Abstract
Background: Cerebral Small Vessel Disease (SVD) can cause cognitive impairment, disability and dementia. While it is still unclear about the pathogenesis of SVD, several risk factors of SVD have been identified, and studies suggested that hypertension may play a critical role in SVD. Furthermore, studies have demonstrated that CYP2J2 isoform, 50 G>T variant, is associated with increasing the risk of ischemic stroke. Thus, we hypothesized that CYP2J2 50 G>T variant is associated with increased risk of cerebral SVD.
Methods: Thus, in this case-control study, we evaluated the association of CYP2J2 polymorphisms with the susceptibility to cerebral SVD in a population of Chinese Han adults.
Results: We found that CYP2J2 50 G>T genotype was significantly higher in SVD patients compared to healthy control group. Furthermore, 50 G>T genotype of CYP2J2 was associated with a significantly higher risk of SVD. Additionally, this polymorphism was significantly associated with WMH volume and a number of impaired cognitive domains in SVD patients.
Conclusion: In conclusion, our study demonstrated that CYP2J2 50 G>T polymorphism is associated with increased risk of cerebral SVD in Han Chinese.
Keywords: CYP2J2, 50 G>T variant, polymorphism, cerebral small vessel disease, cognitive impairment, dementia.
Current Neurovascular Research
Title:Cerebral Small Vessel Disease is Associated with Genetic Variations in CYP2J
Volume: 14 Issue: 4
Author(s): Ming Yao, Daping Lv, Jiajia Huo and Zhongwu Sun*
Affiliation:
- The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui,China
Keywords: CYP2J2, 50 G>T variant, polymorphism, cerebral small vessel disease, cognitive impairment, dementia.
Abstract: Background: Cerebral Small Vessel Disease (SVD) can cause cognitive impairment, disability and dementia. While it is still unclear about the pathogenesis of SVD, several risk factors of SVD have been identified, and studies suggested that hypertension may play a critical role in SVD. Furthermore, studies have demonstrated that CYP2J2 isoform, 50 G>T variant, is associated with increasing the risk of ischemic stroke. Thus, we hypothesized that CYP2J2 50 G>T variant is associated with increased risk of cerebral SVD.
Methods: Thus, in this case-control study, we evaluated the association of CYP2J2 polymorphisms with the susceptibility to cerebral SVD in a population of Chinese Han adults.
Results: We found that CYP2J2 50 G>T genotype was significantly higher in SVD patients compared to healthy control group. Furthermore, 50 G>T genotype of CYP2J2 was associated with a significantly higher risk of SVD. Additionally, this polymorphism was significantly associated with WMH volume and a number of impaired cognitive domains in SVD patients.
Conclusion: In conclusion, our study demonstrated that CYP2J2 50 G>T polymorphism is associated with increased risk of cerebral SVD in Han Chinese.
Export Options
About this article
Cite this article as:
Yao Ming , Lv Daping , Huo Jiajia and Sun Zhongwu *, Cerebral Small Vessel Disease is Associated with Genetic Variations in CYP2J, Current Neurovascular Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567202614666171017151128
DOI https://dx.doi.org/10.2174/1567202614666171017151128 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticholinesterase and Pharmacokinetic Profile of Phenserine in Healthy Elderly Human Subjects
Current Alzheimer Research Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease
Current Alzheimer Research Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients
Current Pharmaceutical Design Therapeutic Approaches Targeting Pathological Tau Aggregates
Current Pharmaceutical Design Tau in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research Management of Glia-Mediated Neuroinflammation and Related Patents
Recent Patents on Inflammation & Allergy Drug Discovery Brain local and regional neuroglial alterations in Alzheimer´s Disease: cell types, responses and implications.
Current Alzheimer Research Acetylcholinesterase: A Primary Target for Drugs and Insecticides
Mini-Reviews in Medicinal Chemistry On the Paradigm Shift Towards Multitarget Selective Drug Design
Current Computer-Aided Drug Design Second-Generation Antipsychotic Agents: A Review of Safety Profiles
Current Psychiatry Reviews New Devices for Treating Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Protein Interaction Studies for Understanding the Tremor Pathway in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions
Current Alzheimer Research Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Functional Biomedical Images of Alzheimer's Disease a Green's Functionbased Empirical Mode Decomposition Study
Current Alzheimer Research The Possible Therapeutic Actions of Peroxisome Proliferator-Activated Receptor α(PPARα) Agonists,PPARγ Agonists,3-Hydroxy-3- Methylglutaryl Coenzyme A (HMG-CoA)Reductase Inhibitors,Angiotensin Converting Enzyme (ACE)Inhibitors and Calcium (Ca)-Antagonists on Vascular Endothelial Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets